Literature DB >> 15784707

In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy.

J P H van Wijk1, M Castro Cabezas, E J P de Koning, T J Rabelink, R van der Geest, I M Hoepelman.   

Abstract

The use of antiretroviral combination therapy in HIV has been associated with lipodystrophy and several metabolic risk factors. We postulated that patients with HIV-lipodystrophy have impaired adipose tissue free fatty acid (FFA) trapping and, consequently, increased hepatic FFA delivery. We investigated FFA, hydroxybutyric acid (HBA; reflecting hepatic FFA oxidation), and triglyceride (TG) changes after a high fat meal in HIV-infected males with (LIPO; n = 26) and without (NONLIPO; n = 12) lipodystrophy and in healthy males (n = 35). Because defective peripheral FFA trapping has been associated with impaired action of complement component 3 (C3), we also determined postprandial C3 concentrations. The LIPO group had higher homeostasis model assessment scores compared with the other groups. Areas under the curve (AUCs) for FFA, HBA, and TG were higher in the LIPO group than in the NONLIPO group or the controls. No differences in TG-AUC, FFA-AUC, and HBA-AUC were observed between the NONLIPO group and controls. In HIV-infected patients, FFA-AUC and HBA-AUC were inversely related to sc adipose tissue area. Plasma C3 showed a postprandial increase in healthy controls, but not in the HIV-infected groups. C3 was not related to body fat distribution, postprandial FFA, or HBA. The present data suggest disturbed postprandial FFA metabolism in patients with HIV-lipodystrophy, most likely due to inadequate incorporation of FFA into TG in sc adipose tissue, but do not support a major role for C3 in these patients. The higher postprandial HBA levels reflect increased hepatic FFA delivery and may aggravate insulin resistance and dyslipidemia, leading to increased cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784707     DOI: 10.1210/jc.2004-2343

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

Review 2.  Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.

Authors:  Erdembileg Anuurad; Alison Semrad; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2009-10       Impact factor: 1.894

3.  Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.

Authors:  Wen Guo; Siu Wong; Jeffrey Pudney; Ravi Jasuja; Ning Hua; Lan Jiang; Andrew Miller; Paul W Hruz; James A Hamilton; Shalender Bhasin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-17       Impact factor: 8.311

4.  Relationship of postprandial nonesterified fatty acids, adipokines, and insulin across gender in human immunodeficiency virus-positive patients undergoing highly active antiretroviral therapy.

Authors:  Guijing Lu; Asha Thomas-Geevarghese; Erdembileg Anuurad; Subhashree Raghavan; Robert Minolfo; Bernard Ormsby; Wahida Karmally; Wafaa M El-Sadr; Jeanine Albu; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2009-06       Impact factor: 1.894

Review 5.  Disordered lipid metabolism and the pathogenesis of insulin resistance.

Authors:  David B Savage; Kitt Falk Petersen; Gerald I Shulman
Journal:  Physiol Rev       Date:  2007-04       Impact factor: 37.312

6.  Impact of cocaine use on protease inhibitor-associated dyslipidemia in HIV-infected adults.

Authors:  Ji Li; Hong Lai; Shaoguang Chen; Shenghan Lai
Journal:  Int J STD AIDS       Date:  2018-02-22       Impact factor: 1.359

Review 7.  Body composition and metabolic changes in HIV-infected patients.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  J Infect Dis       Date:  2012-06       Impact factor: 5.226

8.  Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.

Authors:  Jeroen P H van Wijk; Manuel Castro Cabezas
Journal:  Int J Vasc Med       Date:  2011-08-22

9.  Immunometabolic Reprogramming in Response to HIV Infection Is Not Fully Normalized by Suppressive Antiretroviral Therapy.

Authors:  Pragney Deme; Leah H Rubin; Danyang Yu; Yanxun Xu; Gertrude Nakigozi; Noeline Nakasujja; Aggrey Anok; Alice Kisakye; Thomas C Quinn; Steven J Reynolds; Richard Mayanja; James Batte; Maria J Wawer; Ned C Sacktor; Deanna Saylor; Norman J Haughey
Journal:  Viruses       Date:  2022-06-15       Impact factor: 5.818

10.  Single nucleotide polymorphisms in LCAT may contribute to dyslipidaemia in HIV-infected individuals on HAART in a Ghanaian population.

Authors:  Simon Bannison Bani; Kwabena Owusu Danquah; Christian Obirikorang; William K B A Owiredu; Lawrence Quaye; Edmund Muonir Der; Emmanuel Acheampong; Yussif Adams; Peter Paul M Dapare; Moses Banyeh; Enoch Odame Anto; Samuel Asamoah Sakyi
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.